



Press Release

16 April 2010

Gamma Vaccines receives sponsorship from the ACT Government's Trade Connect (TradeCon) grant scheme to participate in BIO-2010 in Chicago, USA

Canberra-based Gamma Vaccines Pty Ltd has been successful in receiving sponsorship from the ACT government to attend the BIO-2010 in Chicago, USA.

The money has been provided under the Trade Connect (TradeCon) program administered by Business & Development ACT.

Professor Tim Hirst, Executive Chairman of Gamma Vaccines commented "I am delighted by the continuing support of the ACT's Department of Business and Development. This grant will enable us to attend the largest biotechnology conference in the world. It will make it possible for us to interact with numerous potential collaborators and service providers that can assist Gamma Vaccines' clinical development program."

About Gamma Vaccines

Gamma Vaccines Pty Ltd is a new company that is developing a novel vaccine approach to preventing influenza infections. The company's proprietary product is a vaccine that offers broad protective immunity against a wide diversity of influenza virus A strains. The company has received private funding from seed investors as well as grants from the Commercialising Emerging Technologies (COMET) program of the Australian Federal Government and from the ACT Government's Innovation Connect (ICoN) scheme.

About Trade Connect

TradeCon aims to assist ACT companies to build global opportunities and enhance their international competitiveness through an off-shore representation model and small 'step-up' funding grants to facilitate access to an additional range of professional services and activities.

For further information about Gamma Vaccines, please contact:

Professor Tim Hirst
Executive Chairman
Gamma Vaccines Pty Ltd

Tel: +61 (0) 420 942 824

e-mail: tim@gammavaccines.com